Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Etoposide combined with cisplatin or carboplatin, administered every three weeks for a total of four cycles.

Toripalimab was administered concurrently with chemotherapy, every three weeks for four cycles.

Oral surufatinib 200 mg once daily (q.d.), given on days 1-14 of each chemotherapy cycle.

Thoracic radiotherapy will begin no later than the start of the third chemotherapy cycle.

PCI is recommended after the completion of chemoradiotherapy.

Patients achieving complete response (CR), partial response (PR), or stable disease (SD) following chemoradiotherapy will receive consolidation therapy. Toripalimab: 240 mg intravenously on day 1, every three weeks. Surufatinib: 200 mg orally on days 1-14, every three weeks.